Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip).

IF 1.8 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Visceral Medicine Pub Date : 2022-04-01 DOI:10.1159/000522604

Beate Rau, Linda Feldbrügge, Felix Gronau, Miguel Enrique Alberto Vilchez, Peter Thuss-Patience, Pierre Emmanuel Bonnot, Olivier Glehen

{"title":"Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip).","authors":"Beate Rau, Linda Feldbrügge, Felix Gronau, Miguel Enrique Alberto Vilchez, Peter Thuss-Patience, Pierre Emmanuel Bonnot, Olivier Glehen","doi":"10.1159/000522604","DOIUrl":null,"url":null,"abstract":"Background: Gastric cancer (GC) is associated with a poor prognosis mostly due to peritoneal metastasis, which will develop in time during the patient's disease history. To prevent and treat peritoneal metastasis, different kinds of treatment regimens have been described.Summary: In this review, we addressed two main topics - prophylaxis and treatment of peritoneal metastasis in GC. Prevention should be directed towards diminishing cancer cell spillage and reducing adherence of cancer cells to the abdominal cavity. Postoperative washing of the abdomen with or without chemotherapy and additional heat are herein discussed.Key messages: Treatment of existing peritoneal metastasis is effective in patients with limited disease and tumour spread. Cytoreductive surgery including resection of peritoneal metastasis followed directly with hyperthermic intraperitoneal chemotherapy can increase overall survival and progression-free survival in selected patients. Drugs, duration and time schedules of intraperitoneal chemotherapy are reviewed and presented. Intraperitoneal chemotherapy seems to improve the prognosis of patients with GC and peritoneal metastasis after complete resection of both primary and metastatic tumours.","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 2","pages":"81-89"},"PeriodicalIF":1.8000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082209/pdf/vis-0038-0081.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Visceral Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000522604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Gastric cancer (GC) is associated with a poor prognosis mostly due to peritoneal metastasis, which will develop in time during the patient's disease history. To prevent and treat peritoneal metastasis, different kinds of treatment regimens have been described.

Summary: In this review, we addressed two main topics - prophylaxis and treatment of peritoneal metastasis in GC. Prevention should be directed towards diminishing cancer cell spillage and reducing adherence of cancer cells to the abdominal cavity. Postoperative washing of the abdomen with or without chemotherapy and additional heat are herein discussed.

Key messages: Treatment of existing peritoneal metastasis is effective in patients with limited disease and tumour spread. Cytoreductive surgery including resection of peritoneal metastasis followed directly with hyperthermic intraperitoneal chemotherapy can increase overall survival and progression-free survival in selected patients. Drugs, duration and time schedules of intraperitoneal chemotherapy are reviewed and presented. Intraperitoneal chemotherapy seems to improve the prognosis of patients with GC and peritoneal metastasis after complete resection of both primary and metastatic tumours.

查看原文本刊更多论文

胃癌(胃脘痛、胃脘痛)热腹腔化疗的适应证。

背景:胃癌(胃癌)预后较差，主要是由于腹膜转移，这种转移会在患者的病史中及时发生。为了预防和治疗腹膜转移，不同的治疗方案已经被描述。摘要:在这篇综述中，我们讨论了两个主要主题-胃癌腹膜转移的预防和治疗。预防应针对减少癌细胞溢出和减少癌细胞粘附腹腔。术后腹部清洗有或没有化疗和额外的热量在这里讨论。关键信息:现有腹膜转移的治疗对疾病有限和肿瘤扩散的患者有效。包括切除腹膜转移的细胞减少手术，直接配合腹腔内高温化疗，可以提高选定患者的总生存期和无进展生存期。本文回顾并介绍了腹腔化疗的药物、持续时间和时间安排。腹腔内化疗似乎可以改善胃癌和腹膜转移患者在原发和转移性肿瘤完全切除后的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Visceral Medicine Medicine-Surgery

CiteScore

4.50

自引率

0.00%

发文量

期刊介绍： This interdisciplinary journal is unique in its field as it covers the principles of both gastrointestinal medicine and surgery required for treating abdominal diseases. In each issue invited reviews provide a comprehensive overview of one selected topic. Thus, a sound background of the state of the art in clinical practice and research is provided. A panel of specialists in gastroenterology, surgery, radiology, and pathology discusses different approaches to diagnosis and treatment of the topic covered in the respective issue. Original articles, case reports, and commentaries make for further interesting reading.